发明授权
- 专利标题: Diaryl ureas for diseases mediated by PDGFR
- 专利标题(中): 由PDGFR介导的疾病的二芳基脲
-
申请号: US10848567申请日: 2004-05-19
-
公开(公告)号: US08796250B2公开(公告)日: 2014-08-05
- 发明人: Scott Wilhelm , Jacques Dumas , Gaetan Ladouceur , Mark Lynch , William Scott
- 申请人: Scott Wilhelm , Jacques Dumas , Gaetan Ladouceur , Mark Lynch , William Scott
- 申请人地址: US NJ Whippany
- 专利权人: Bayer Healthcare LLC
- 当前专利权人: Bayer Healthcare LLC
- 当前专利权人地址: US NJ Whippany
- 代理机构: Millen, White, Zelano & Branigan, P.C.
- 主分类号: A01N43/00
- IPC分类号: A01N43/00 ; A61K31/33 ; A61K31/66 ; A61K45/06 ; A61L31/16 ; A61K31/4418 ; A61K31/165 ; A61K31/4412 ; A61K31/00 ; A61K31/443 ; G01N33/574 ; A61K31/16 ; G01N33/50
摘要:
The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.
公开/授权文献
- US20050059703A1 Diaryl ureas for diseases mediated by PDGFR 公开/授权日:2005-03-17